Jafron Biomedical Co.,Ltd.

Shenzhen Stock Exchange 300529.SZ

Jafron Biomedical Co.,Ltd. EBIT for the year ending December 31, 2023: USD 81.17 M

Jafron Biomedical Co.,Ltd. EBIT is USD 81.17 M for the year ending December 31, 2023, a -46.82% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Jafron Biomedical Co.,Ltd. EBIT for the year ending December 31, 2022 was USD 152.64 M, a -31.78% change year over year.
Jafron Biomedical Co.,Ltd. EBIT for the year ending December 31, 2021 was USD 223.76 M, a 41.36% change year over year.
Jafron Biomedical Co.,Ltd. EBIT for the year ending December 31, 2020 was USD 158.29 M, a 64.15% change year over year.
Jafron Biomedical Co.,Ltd. EBIT for the year ending December 31, 2019 was USD 96.43 M, a 40.13% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shenzhen Stock Exchange: 300529.SZ

Jafron Biomedical Co.,Ltd.

CEO	Mr. Fan Dong
IPO Date	Aug. 2, 2016
Location	China
Headquarters	No. 98 Keji 6th Road
Employees	2,408
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials Medical Instruments

Description

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and marketing of biological materials and medical devices in China. It offers solutions for kidney, liver, critical, and rheumatism diseases, as well as poisoning; adsorption products and blood purification machines; and other products, such as single use arteriovenous puncture, hemodialysis online dry powder bags/cylinders, disinfectants, hemodialysis concentrates, and medical adsorbable suture with needles. The company offers its products in Germany, Italy, Turkey, Thailand, Vietnam, the Philippines, South Africa, Kenya, Chile, Peru, and the United Arab Emirates. Jafron Biomedical Co.,Ltd. was founded in 1989 and is based in Zhuhai, China.

Key trends

Past 5 years